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Differences between glioblastomas and primary central nervous system lymphomas in
1H-Magnetic Resonance Spectroscopy
Abstract:
Purpose: The present study aimed to distinguish between glioblastomas and primary
central nervous system lymphomas (PCNSLs) using 1H-Magnetic Resonance Spectroscopy
(MRS), especially glutamate (Glu) / creatine (Cr) and Glu/Glu + glutamine (Gln) ratios.
Materials and methods: A total of 46 patients (31 cases diagnosed with glioblastoma, 15
with PCNSL) were examined by in vivo single-voxel proton 1H-MRS with a 3-T MR
imaging system. Differences in absolute concentration of Cr, choline/Cr, lipid (1.3ppm)/Cr,
Glu+Gln/Cr, Glu /Cr, and Glu/Glu+Gln ratios among groups were evaluated with
Mann-Whitney U test.
Results: PCNSLs (3.408 ± 1.194 [standard deviation]) showed significantly higher Glu/Cr
ratios as compared to glioblastomas (2.220 ± 0.942; P= 0.003) (Glu/Cr cutoff ratio of 2.509
showed a sensitivity of 88% (7/8) and a specificity of 92% (22/24)), while glioblastomas
(0.539 ± 0.098) showed significantly lower Glu/Glu+Gln ratios as compared to PCNSLs
(0.728 ± 0.147; P<0.001) (Glu/Glu+Gln cutoff ratio of 0.558 showed a sensitivity of 69%
(18/26) and a specificity of 100% (13/13)). And PCNSLs (1.101 ± 0.387) showed
significantly higher Cho/Cr ratios as compared to glioblastomas (0.850 ± 0.465; P= 0.026).
Conclusion: Glu/Cr, Glu/Glu+Gln, and Cho/Cr ratios may be useful in distinguishing








Therapies for glioblastomas and primary central nervous system lymphomas (PCNSLs)
differ, making it especially important to correctly diagnose these tumors. It is sometimes
difficult to distinguish them on routine imaging studies and most patients receive
pathological confirmation prior to treatment (Figure 1).
In 1H- magnetic resonance spectroscopy (MRS), both glioblastomas and PCNSLs
usually show depression of the creatine (Cr) peaks, elevation of the choline (Cho) peak, and
elevation of the lipid (Lip) and/or lactate peak. With regard to Lip, PCNSLs have been
reported to show higher Lip/Cr ratios from the contrast-enhancing regions than
glioblastomas in which the voxel could be placed in solid tissue without macroscopic
evidence of necrosis [1]. But it is often difficult to set voxels excluding necrotic area,
especially in glioblastomas. As for Cho, PCNSLs have been reported to show higher Cho/Cr
ratios from the contrast-enhancing regions than glioblastomas [1], while another study found
that Cho/Cr ratios from the contrast-enhancing regions do not differ significantly between
them [2]. These results emphasize that the patterns of 1H-MRS in glioblastomas and PCNSLs
are diverse, indicating the need to evaluate other peaks to distinguish them more precisely.
With regard to glutamate (Glu), almost 85% of all synapses in the brain are
glutamatergic, making Glu a central molecule in the brain [3]. Besides its role in
neurotransmission, Glu is a key molecule in synapse formation, dendrite pruning, cell
migration, differentiation, and death [4]. As for glutamine (Gln), Glu and Gln are metabolites
of the same metabolic pathway. For example, extracellular Glu released from the neuron is
avidly taken up by the Glu transporters in glial cells, and Glu is rapidly converted to Gln by
Gln synthetase in the glial cells. In vivo 1H-MRS, Glu and Gln are usually collectively
evaluated by Glu+Gln. Because the chemical shift difference between Glu and Gln in
1H-MRS is small, it can be difficult to distinguish them (Figure 1d, 1e). The independent
quantification of Glu and Gln can be considerably improved by moving from 1.5T to 3T.
With regard to Glu+Gln, it has been reported that Glu+Gln/Cr ratios from contrast-enhancing
regions do not differ significantly between glioblastomas and PCNSLs [2]. No differences in
Glu or Gln alone in in vivo 1H-MRS between them have been reported, to the extent that we
could determine.
On the other hand, it has been reported that in high-grade gliomas (World Health
Organization grades III and IV), microdialysates in the tumor periphery consistently show
significantly higher extracellular Glu relative to microdialysates in non-tumoral regions,
unlike PCNSL [5]. And, high extracellular Glu has been noted to stimulate Gln synthetase
and promote the synthesis of Gln from Glu in cultured astrocytes [6].
Based on these reports, we hypothesized that in glioblastomas due to high
extracellular Glu the synthesis of Gln from Glu would be promoted [6], and so Glu/Glu+Gln
ratios might be lower than those in PCNSLs. The purpose of this study was to analyze the
differences in the 1H-MRS findings among glioblastomas and PCNSLs with special
reference to Glu and Gln expression.
Materials and Methods:
Patients:
This retrospective analysis of the data was approved by the institutional review board of our
university. All patients gave informed consent prior to inclusion in this study. All patients
were introduced to our institution for further examination of their brain tumors from April
2011 to June 2014. All of them had normal immunocompetence. The study focused on 31
patients with glioblastoma and 15 patients with PCNSL. The diagnosis was verified by
stereotactic biopsy, endoscopic transventricular biopsy, open biopsy, and surgical resection.
Clinical parameters in the analyzed groups are summarized in Table 1. All tumors were
confirmed histopathologically after preoperative diagnosis with magnetic resonance imaging
(MRI) and 1H-MRS, and were not subjected to biopsy, surgical resection, chemotherapy or
radiation therapy before the preoperative diagnosis with MRI and 1H-MRS. We excluded the
cases in which the lesion was < 1 cm in diameter, with 1 case diagnosed as PCNSL thus
excluded. Two patients with glioblastoma and 7 with PCNSL had multiple mass lesions in
the brain, and these patients were subjected to 1H-MRS in only 1 mass lesion each. So, in the
present study, we used only one set of data for each patient. When multiple mass lesions
were present, we determined the mass lesion that seemed the most suitable for gaining
reliable 1H-MRS (size, homogenous lesion, and so on).
1H-MR Spectroscopic Acquisition Protocols:
MRI and single voxel 1H-MRS examinations were performed on a SIGNA HDxt 3.0T MR
scanner (GE Healthcare) using a standard quadrature head coil. Spectroscopic imaging
studies were performed after contrast injection in all patients (intravenous administration of
0.1 mmol per kilogram of body weight of gadolinium-based contrast material (Gd-DTPA
Magnevist; Schering, Berlin, Germany, or Gd-DTPA-BMA Omniscan; Nycomed, Oslo,
Norway)). Point-resolved single voxel spectroscopy (PRESS) was used to obtain 1H-MRS
using repetition time (TR) at 1500 ms, echo time (TE) at 35 ms, and number of excitations
(NEX) = 128. Water suppression and fat suppression were done on default (3-pulse chemical
shift selection suppression (CHESS)). Size and position of volume of interest (VOI) were
determined by examining the MR images in all three dimensions (sagittal, coronal, and
transverse planes). The size of a VOI (3.7 ~ 32.6 ml) was changed according to the size of
the lesions. Voxels were centered in the area of contrast-enhancement when present, with
minimal contamination from the surrounding nontumoral tissue, based on the initial
screening examination. Outer volume suppression (OVS) around the VOI was added if
needed (Figure 2). To avoid bias, we did not exclude any cases due to improper positioning
of the VOI.
1H-MR Spectroscopic Postprocessing, Analysis, and Metabolite Quantification:
The tumor shapes were variable, often making it difficult to exclude necrotic and
surrounding normal areas (Figure 2). So, to compare the differences in the necrotic area in
the VOIs between glioblastomas and PCNSLs, first we defined the lesion surrounded by
enhanced lesion as ‘tumor’ temporarily. Then we counted pixels within VOI and calculated
the ratio between the area of unenhanced lesion in ‘tumor’ and the area of whole ‘tumor’ in
the VOI. And, to compare the differences in the surrounding normal area in the VOI between
glioblastomas and PCNSLs, we calculated the ratio between the area of ‘tumor’ and the area
of the VOI. We measured Cr as a constituent of all cells, Cho as an indicator of phospholipid
membrane turnover, Lip as an indicator of cellular destruction and lipid-laden cells, Glu+Gln
as a major neurotransmitter and its metabolite, and Glu alone. Cr, Cho, Lip at 1.3 parts per
million (ppm) (Lip (1.3 ppm)), Glu+Gln and Glu were determined using Linear Combination
of Model spectra (LCModel; S Provencher, Canada) (Version 6.3-0C; this version is
available for lipid of tumor option) [7-8]. Estimated concentrations with Cramer-Rao lower
bounds (CRLB) of below 20% standard deviation (SD) were regarded as recommended in
the original published model [7-8]. The selection of metabolites depending on %SD might
result in the exclusion of low concentration metabolites, possibly biasing the results. So, we
showed the results of both unselected and selected data depending on %SD in this study.
Necrosis is characteristic of glioblastomas [9], which makes it difficult to set the
voxel in solid tissue without macroscopic evidence of necrosis (Figure 2). And because of
cellular loss due to necrosis, comparing metabolites among these tumors using absolute
concentrations is problematic. Cr has often been regarded as a stable metabolite and has
subsequently been used as a reference metabolite. So in the present study, to compare
metabolites among these tumors, we used Cho/Cr, Lip (1.3 ppm)/Cr, Glu+Gln/Cr, and
Glu/Cr ratios of each tumor, and the absolute concentration of Cr was compared among these
tumors. And, to compare differences in Glu-Gln cycles among these tumors, we used
Glu/Glu+Gln. With LCModel, values of Glu, Glu+Gln and Gln are obtained automatically.
Regarding Gln, Gln at estimated concentrations with CRLB of below 20% SD could be
distinguished in only a few cases in PCNSLs. And to avoid the effect of cellular loss by
necrosis, we did not use absolute concentrations of Glu and Glu+Gln, but used their ratios.
These analyses and calculations were performed by a physician who was aware of the nature
of the study and clinical data.
Statistical Analysis:
Differences in the absolute concentration of Cr, Cho/Cr, Lip (1.3 ppm)/Cr, Glu+Gln/Cr,
Glu/Cr, and Glu/Glu+Gln ratios among groups were evaluated with Mann-Whitney U test. P
values <0.05 were considered statistically significant. The value at which the receiver
operating characteristic (ROC) curve was closest to point (0,1) was considered as the
optimum threshold value. All analyses were performed with the open-source software for
statistical computing and graphics (R, version 2.5, Department of Statistics and Mathematics,
University of Vienna, Vienna, Austria; www.r-project.org) by a physician who was aware of
the nature of the study and clinical data.
Results:
The differences in VOIs between glioblastomas and PCNSLs are summarized in Table 2.
The number of cases whose ratios at estimated concentrations with CRLB of below 20% SD
in the analyzed groups is summarized in Table 3.Values of ratios in the analyzed groups
(mean ± SD) and P values of ratios between the analyzed groups are summarized in Table 4
(CRLB of all % SD) and Table 5 (CRLB of below 20% SD). The scatterplots are shown in
Figure 3 (CRLB of all % SD) and Figure 4 (CRLB of below 20% SD).
VOI
Regarding the ratio between the area of unenhanced lesion in ‘tumor’ and the area of whole
‘tumor’ in the VOI, glioblastomas showed significantly higher values compared to PCNSLs
(P<0.001). For the ratio between the area of ‘tumor’ and the area of the VOI, the difference
between glioblastomas and PCNSLs was not significant (P=0.320).
Cr in 1H-MRS (CRLB of all % SD):
PCNSLs showed significantly lower Cr values compared to glioblastomas (P=0.010).
Cr in 1H-MRS (CRLB of below 20% SD):
The difference between glioblastomas and PCNSLs was not significant (P=0.234).
Cho/Cr in 1H-MRS (CRLB of all % SD):
PCNSLs showed significantly higher Cho/Cr ratios compared to glioblastomas (P=0.001).
Cho/Cr in 1H-MRS (CRLB of below 20% SD):
PCNSLs showed significantly higher Cho/Cr ratios compared to glioblastomas (P=0.026).
Cho/Cr ratios of greater than 0.627 as an indicator of PCNSLs rather than glioblastomas
showed a sensitivity of 100% (13/13) and a specificity of 35% (10/29) (Figure 4).
Lip (1.3 ppm)/Cr in 1H-MRS (CRLB of all % SD):
PCNSLs showed significantly higher Lip (1.3 ppm)/Cr ratios compared to glioblastomas
(P=0.008).
Lip (1.3 ppm)/Cr in 1H-MRS (CRLB of below 20% SD):
There were no significant differences between glioblastomas and PCNSLs (P=0.431).
Lipid shows a wide peak. With LCModel, for differences in chemical shift (ppm),
lipid peak values are obtained at 2.0, 1.3, and 0.9 ppm. In the present study, using only Lip
(1.3 ppm)/Cr. Because both Lip (2.0 ppm)/Cr and Lip (0.9 ppm)/Cr at estimated
concentrations with CRLB of below 20% SD could be distinguished in only a few cases, so
it was difficult to compare the values of Lip (2.0 ppm)/Cr and Lip (0.9 ppm)/Cr among the
analyzed groups.
Lactate (Lac) is a marker of the anaerobic metabolic state of tumors. Lac/Cr at
estimated concentrations with CRLB of below 20% SD could be distinguished in only a few
cases in lymphomas.
Glu+Gln/Cr in 1H-MRS (CRLB of all % SD):
PCNSLs showed significantly higher Glu+Gln/Cr ratios compared to glioblastomas
(P=0.004).
Glu+Gln/Cr in 1H-MRS (CRLB of below 20% SD):
The difference between glioblastomas and PCNSLs was not significant (P=0.099).
Glu/Cr in 1H-MRS (CRLB of all SD):
PCNSLs showed significantly higher Glu/Cr ratios compared to glioblastomas (P<0.001).
Glu/Cr in 1H-MRS (CRLB of below 20% SD):
PCNSLs showed significantly higher Glu/Cr ratios compared to glioblastomas (P=0.003).
Glu/Cr ratios of greater than 2.509 as an indicator of PCNSLs rather than glioblastomas
showed a sensitivity of 88% (7/8) and a specificity of 92% (22/24) (Figure 4).
Glu/Glu+Gln in 1H-MRS (CRLB of all SD):
Glioblastomas showed significantly lower Glu/Glu+Gln ratios compared to PCNSLs
(P<0.001).
Glu/Glu+Gln in 1H-MRS (CRLB of below 20% SD):
Glioblastomas showed significantly lower Glu/Glu+Gln ratios compared to PCNSLs
(P<0.001). As an indicator of glioblastomas as compared to PCNSLs Glu/Glu+Gln ratios
<0.558 showed a sensitivity of 69% (18/26) and a specificity of 100% (13/13)) (Figure 4).
With LCModel, values of Glu, Glu+Gln and Gln are obtained automatically.
Regarding Gln, Gln at estimated concentrations with CRLB of below 20% SD could be
distinguished in 18 of 31 glioblastomas (58%), but only in 2 of 15 PCNSLs (13%). This
made it difficult to compare their Gln values.
Discussion:
Several studies have reported differences between glioblastomas and PCNSLs in 1H-MRS [1,
2]. In the present study, Cho/Cr, Glu/Cr, and Glu/Glu+Gln ratios showed significant
differences between glioblastomas and PCNSLs among both unselected and selected data
depending on %SD.
The selection of metabolites depending on CRLB of below 20% SD might result in
the exclusion of low concentration metabolites. So, we showed the results of both unselected
and selected data depending on %SD. In LCModel, use of the data depending on CRLB of
below 20% SD is recommended [7-8].
Cr has often been regarded as a stable metabolite, and has subsequently been used as
a reference metabolite in 1H-MRS. In this study, glioblastomas contained a significantly
larger necrotic area in the VOI as compared to PCNSLs. So, to compare metabolites among
these tumors, we used not absolute concentrations but rather ratios between metabolites and
Cr. Among unselected data depending on % SD, PCNSLs showed significantly lower Cr
values compared to glioblastomas, and so it would not be proper to use Cr as a reference
metabolite for comparing glioblastomas and PCNSLs. Unlike data depending on below 20%
SD, PCNSLs showed significantly higher Cho/Cr, Lip (1.3ppm)/Cr, and Glu+Gln/Cr ratios
compared to glioblastomas in unselected data depending on % SD, but it would be difficult
to conclude whether these results are useful. On the other hand, among selected data
depending on CRLB of below 20% SD, the absolute concentration of Cr did not differ
significantly between glioblastomas and PCNSLs.
Both glioblastomas and PCNSLs usually show elevation of Cho/Cr in 1H-MRS.
PCNSLs have been reported to show higher Cho/Cr ratios than glioblastomas [1], while
another study found that Cho/Cr ratios do not differ significantly between them [2]. In the
present study, PCNSLs showed significantly higher Cho/Cr ratios as compared to
glioblastomas, though the difference in Cho/Cr was smaller than those in Glu/Cr and
Glu/Glu+Gln. The increased Cho peak in studies of tumors has been attributed to increased
cellularity and rapid membrane turnover [10]. And it has been reported that PCNSLs have
significantly lower apparent diffusion coefficient (ADC) values compared to glioblastomas
due to their higher cellularity [11, 12]. Such a difference in cellularity might have affected
the results.
It has been reported that PCNSLs have higher Lip/Cr than glioblastomas in which the
voxel could be placed without macroscopic evidence of necrosis [1]. In this report,
glioblastomas from which VOI contained macroscopically evident necrosis showed
massively elevated Lip/Cr compared to glioblastomas from which VOI did not contain
macroscopic evidence of necrosis [1]. In the present study, VOIs were centered in
non-necrotic parts of the tumors, but could contain some necrotic parts, especially in
glioblastomas. And in the present study, although lipid shows a wide peak, we could
evaluate differences only at 1.3ppm. These results may be related to the fact that Lip/Cr did
not differ between glioblastomas and PCNSLs significantly among selected data depending
on below 20% SD in the present study.
With regard to Glu and Gln, Glu is largely synthesized de novo in the neurons and
glial cells. Extracellular Glu released from neurons into the synaptic cleft is avidly taken up
by the Glu transporters in glial cells, and Glu is rapidly converted to Gln by Gln synthetase
in the glial cells [4, 13, 14]. It has been reported that extracellular Glu accumulation is
induced as a result of decreased functional glial Glu transporter activity in glioblastomas [15,
16]. It has also been reported that high extracellular Glu inhibits glial Glu transporter
expression and stimulates Gln synthetase expression in cultured astrocytes [6]. In other
words, glioblastomas show elevated levels of extracellular Glu as a result of decreased
functional glial Glu transporter activity. In surrounding glial cells, high extracellular Glu
inhibits uptake of Glu thereby leading to further increases in extracellular Glu, while high
extracellular Glu stimulates Gln synthetase expression and promotes the synthesis of Gln
from Glu. In this way, Glu/Glu+Gln ratios in glioblastomas might decrease as compared with
those in normal glial cells. We could not find any pertinent studies regarding the Glu-Gln
cycle in PCNSLs.
As for Glu+Gln/Cr, a significant relation has been identified between the tissue
Glu+Gln concentration and glucose metabolism in human cortex using
18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) and
1H-MRS [17], with PCNSLs found to have significantly higher SUV max and SUV average
than high-grade gliomas and brain metastases with 18F-FDG PET [18]. In the present study,
though the difference was not significant, PCNSLs tended to show higher Glu+Gln/Cr ratios
compared to glioblastomas, while Cr did not differ significantly between them. These results
may be attributable to the fact that glucose metabolism and Glu+Gln concentration are in
some way related in the cerebral cortex and that PCNSLs show significantly higher SUV
max in 18F-FDG PET as compared to high-grade gliomas.
With regard to Glu/Cr, PCNSLs showed significantly higher Glu/Cr relative to
glioblastomas in the present study. This would appear to be due to their significantly higher
Glu/Glu+Gln and higher Glu+Gln/Cr (but not statistically significant) compared to those of
glioblastomas.
In this study, there were significant differences between glioblastomas and PCNSLs
in Glu/Cr and Glu/Glu+Gln. This might be attributable to some differences in the Glu-Gln
cycle and glucose metabolism. But several other factors also seem to have contributed to
these results. For example, in this study, glioblastomas contained more necrotic lesion than
PCNSLs, which might have affected the results. And it has been reported that PCNSLs have
significantly ADC values compared to glioblastomas due to their higher cellularity [11, 12].
Such a difference in cellularity might have affected the results.
About absolute concentrations of metabolites in tumors as determined by in vitro
1H-MRS, it has been reported that glioblastomas show very increased glycine concentration
and PCNSLs show four to five times increased phosphorylethanolamine (PEA)
concentration as compared with normal brain [19]. Glycine and PEA are not obtained
automatically with LCModel, and so we did not evaluate them in the present study.
The following limitations were present in the present study. First, it was retrospective
in nature, and the number of patients was limited. Second, the physician who performed the
analyses and calculations was not blinded to the clinical data. Third, there is difficulty in
resolving Glu and Gln from Glu+Gln in 1H-MRS. Because the chemical shift difference
between Glu and Gln in 1H-MRS is small, it can be difficult to distinguish the two
metabolites (Figure 1d, 1e). In this study, we showed the results of both unselected and
selected data depending on %SD. In PCNSLs and healthy participants, Gln/Cr that met this
criterion could be distinguished in only a few cases. So, we could not evaluate Gln/Cr among
the analyzed groups. Fourth, contrast material may affect 1H-MRS. An average 15%
decrease in the peak area of Cho-containing compounds after administration of contrast
material has been reported [20, 21]. And, it has been noted that the influence of contrast
medium on MR spectroscopy differs depending on the structure of the component, with
GD-DTPA more efficient in enhancing relaxation of Cho than GD-DOTA and
GD-DTPA-BMA [22]. In this study, we used a different type of contrast medium in each
patient, and so the results may have been influenced by the type of contrast medium. Another
study found no statistically significant differences before and after contrast in the Cho peak
area in the tumor, nor in the contralateral hemisphere [23]. With regard to Glu+Gln and Glu,
we could not find any relevant studies, and so cannot draw any conclusions about the effect
of contrast material on them. In the present study, 1H-MRS studies were performed after
contrast injection in all patients because abnormal enhancement seems to be useful in
guiding VOI localization. Fifth, in single voxel 1H-MRS, VOI may contain not only tumors
but also peritumoral lesions. In the present study, to avoid peritumoral lesions as much as
possible, OVS around the VOI was added if needed. And the difference in the surrounding
normal area in the VOI between glioblastoma and PCNSL was not significant. Sixth, it was
difficult to set the voxel in solid tissue without macroscopic evidence of necrosis, especially
in glioblastomas. Because of cellular loss due to necrosis, comparing metabolites among
these tumors using absolute concentrations seemed to be difficult, and so instead we
compared the ratios of each metabolite with Cr. Seventh, in 1H-MRS, estimated metabolic
concentration ratios differ according to location. VOIs could contain various percentages of
white matter and cortical gray matter. It has been reported that the estimated absolute
concentrations of Cr, Glu, and Glu+Gln are higher in white matter than in cortical gray
matter, but Glu+Gln/Cr and Glu/Cr are not so different between white matter and cortical
gray matter as compared to Cho/Cr and N-acetyl Aspartate (NAA)/Cr [24]. Eigth,
Point-resolved single voxel spectroscopy (PRESS) was used to obtain 1H-MRS using
repetition time (TR) at 1500 ms, echo time (TE) at 35 ms. But TR=1500 ms seems to be too
short for accurate peak ratio evaluation due to the difference in T1 of each peak. Using a
long TR of at least 4000 ms is recommended in the original published model [7-8]. .
In conclusion, our results suggest that Glu/Cr, Glu/Glu+Gln, and Cho/Cr as
determined by in vivo single-voxel proton 1H-MRS may be helpful in the differentiation of
glioblastomas and PCNSLs. We anticipate that the precise mechanisms underlying these
results will be elucidated in future studies.
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Figure 1:
Contrast-enhanced (CE) T1 weighted image (T1WI) (Figure 1a), diffusion weighted image
(DWI) (1b), apparent diffusion coefficient (ADC) (1c), glutamate (Glu) peak in 1H- magnetic
resonance spectroscopy (MRS) (1d, gray bold line), and glutamine (Gln) peak in 1H-MRS (1e,
gray bold line).
A 71-year-old man. Mass formation was present on the left temporal lobe (1a). The
mass lesion showed definite hyper intensity on DWI (1b), and a low ADC value (1c). So in
magnetic resonance imaging (MRI), because of high intensity on DWI and the low ADC
value, primary central nervous system lymphoma (PCNSL) was suspected [16-17]. In
1H-MRS, Glu/Cr ratio indicated glioblastoma (Glu/Cr ratio =2.080 (<2.509)), Glu/Glu+Gln
ratio indicated PCNSL (Glu/Glu+Gln ratio =0.587 (>0.558)). In the present study, about
31% of glioblastomas showed Glu/Glu+Gln ratio >0.558, about 92% of glioblastomas
showed Glu/Cr ratio <2.509. So in this case, glioblastoma was suspected in 1H-MRS.
Eventually, glioblastoma was confirmed histopathologically.
Figure 2:
Axial CE T1WI (Figure 2a), sagittal CE T1WI (2b), and coronal CE T1WI (2c).
Voxels were centered in the area of contrast-enhancement. It was difficult to set the
voxel in solid tissue without macroscopic evidence of necrosis. To avoid peritumoral lesions
as much as possible, outer volume suppression (OVS) around the VOI was added.
Figure 3:
The data depending on CRLB of all % SD. Absolute concentration of Cr (Figure 3a), Cho/Cr
ratios (3b), Lip(1.3ppm)/Cr ratios (3c), Glu+Gln/Cr ratios (3d), Glu/Cr ratios (3e), and
Glu/Glu+Gln ratios (3f) in the analyzed groups.
*: significant difference (P<0.05) between the analyzed groups, P values were
determined with Mann-Whitney U test. GBM: glioblastoma, PCNSL: primary central
nervous system lymphoma.
Figure 4:
The data depending on CRLB of below 20% SD. Absolute concentration of Cr (Figure 4a),
Cho/Cr ratios (Figure 4b), Lip(1.3ppm)/Cr ratios (4c), Glu+Gln/Cr ratios (4d), Glu/Cr ratios
(4e), and Glu/Glu+Gln ratios (4f) in the analyzed groups.
Glu/Cr ratios of greater than 2.509 as an indicator of PCNSLs rather than
glioblastomas showed a sensitivity of 88% (7/8) and a specificity of 92% (22/24). As an
indicator of glioblastomas as compared to PCNSLs Glu/Glu+Gln ratios <0.558 showed a
sensitivity of 69% (18/26) and a specificity of 100% (13/13)).
*: significant difference (P<0.05) between the analyzed groups, P values were
determined with Mann-Whitney U test. GBM: glioblastoma, PCNSL: primary central
nervous system lymphoma
Figure 5:
Contrast-enhanced (CE) T1 weighted image (T1WI) (Figure 5a), glutamate (Glu) peak in 1H-
magnetic resonance spectroscopy (MRS) (5b, gray bold line), and glutamine (Gln) peak in
1H-MRS (5c, gray bold line).
1H-MRS in a case of PCNSL. Glu peak is prominent compared to Gln peak.
Figure 6:
Contrast-enhanced (CE) T1 weighted image (T1WI) (Figure 6a), glutamate (Glu) peak in 1H-
magnetic resonance spectroscopy (MRS) (6b, gray bold line), and glutamine (Gln) peak in
1H-MRS (6c, gray bold line).

































































































Clinical Parameters in the analyzed groups





age (mean ± SD) 66.1±11.0 68.2±10.1
The means that the diagnosis was verified
glioblastoma PCNSL
stereotactic biopsy 0 10
endoscopic 1 0
open biopsy 0 5
surgical resection 30 0
Table 2
Ratio of area in VOI
glioblastoma PCNSL P value
CE(-) lesion in 'tumor'*
/' tumor'* 0.100 ± 0.125 0.002 ± 0.008 < 0.001
tumor'* / VOI 0.810 ± 0.174 0.854 ± 0.133 0.320
* we defined the lesion surrounded by enhanced lesion as ‘tumor’ temporarily
Table 3
Number of cases that ratios at estimated concentrations with Cramer-Rao lower bounds of below 20% SD*
glioblastoma PCNSL
Cr 29/31 (94%) 9/15 (60%)
Cho/Cr 29/31 (94%) 9/15 (60%)
Lip(1.3ppm)/Cr 17/31 (55%) 6/15 (40%)
Glu+Gln/Cr 28/31 (90%) 8/15 (53%)
Glu/Cr 24/31 (77%) 8/15 (53%)
Glu/Glu+Gln 26/31 (84%) 13/15 (87%)
*Estimated concentrations with Cramer-Rao lower bounds of below 20% standard deviation (SD)
(analyses with LCModel) were regarded as recommended in the original published model (7-8)
Table 4
Values of ratios in the analyzed groups (mean ± SD) and P values of ratios between the analyzed groups
(cases that ratios at estimated concentrations with Cramer-Rao lower bounds of all %SD)
glioblastoma PCNSL P
Cr 2.476 ± 1.251 1.413 ± 1.098 0.010
Cho/Cr 1.105 ± 1.087 4.175 ± 6.551 0.001
Lip(1.3ppm)/Cr 18.271 ± 20.721 94.144 ± 124.540 0.008
Glu+Gln/Cr 5.385 ± 6.651 13.564 ± 18.993 0.004
Glu/Cr 2.647 ± 2.892 11.497 ± 19.095 < 0.001
Glu/Glu+Gln 0.530 ± 0.146 0.748 ± 0.145 < 0.001
Note.—P values were determined with Mann-Whitney U test
Table 5
Values of ratios in the analyzed groups (mean ± SD) and P values of ratios between the analyzed groups
(cases that ratios at estimated concentrations with Cramer-Rao lower bounds of below 20% SD)
glioblastoma PCNSL P
Cr 2.616 ± 0.902 2.075 ± 1.040 0.234
Cho/Cr 0.850 ± 0.465 1.101 ± 0.387 0.026
Lip(1.3ppm)/Cr 21.262 ± 16.541 33.016 ± 28.505 0.431
Glu+Gln/Cr 3.996 ± 1.895 5.297 ± 1.936 0.099
Glu/Cr 2.220 ± 0.942 3.408 ± 1.194 0.003
Glu/Glu+Gln 0.539 ± 0.098 0.728 ± 0.147 < 0.001
Note.—P values were determined with Mann-Whitney U test
